Compare Medtronic PLC (MDT) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Wendys Co — how do they compare? Medtronic PLC trades at $88.78 (market cap $116.07B), while Wendys Co trades at $7.68 (market cap $1.44B). The key difference: Medtronic PLC is far larger — about 80.6× Wendys Co's market cap, and Wendys Co pays the higher dividend (3.71%). Which is the better fit depends on your goals.
| MDT | WEN | |
|---|---|---|
Market Cap | $116.07B | $1.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $105.35 | $10.68 |
52-Week Low | $73.75 | $6.17 |
Enterprise Value | $134.82B | $5.17B |
Dividend Yield | 3.18% | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $89.41, up 2.58% on the day, reflecting positive momentum. The stock exhibits bullish technical signals with strong moving average support and a consensus analyst price target of $98.75. Fundamentally, the company reported revenue of $33.54B for 2025 with a net income margin of 13.2%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights institutional acquisitions and positive developments in medical technology platforms.
The outlook for MDT is positive, driven by earnings beats, robust cash flow, and growth in cardiac and robotic surgery segments. Key opportunities include undervaluation relative to analyst targets and dividend stability. Risks involve rising debt levels and competitive pressures in the medtech sector. The stock presents a compelling case for growth-oriented income investors.
Wendy's stock (WEN) trades at $7.30, down 5.07% amid significant operational challenges. The company faces declining U.S. traffic, a 50% dividend cut, and loss of its position as America's second-largest burger chain to Burger King. Despite beating Q2 2026 EPS estimates ($0.18 vs. $0.16 expected), revenue trends remain weak with profit margins contracting from 7.58% in 2025 to 5.72% projected for 2026. Technical indicators show bearish momentum with key support at $7.00.
The outlook remains challenging as new CEO Bob Wright implements a turnaround strategy. While valuation appears reasonable (P/E 11.44, P/S 0.65), execution risks are elevated given competitive pressures and $2.66 billion debt load. Analyst sentiment is mixed with 62.75% hold ratings, reflecting uncertainty about the company's ability to regain market share and improve franchisee economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
